Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | May 23, 2023 | May 24, 2023 |
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | January 11, 2021 | January 13, 2021 |
| GERON CORPGERN · Entity 4989 | Director | May 21, 2025 | May 22, 2025 |
| SUTRO BIOPHARMA, INC.STRO · Entity 5797 | Director | September 26, 2018 | September 27, 2018 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 07, 2022 | June 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date May 23, 2023 · Filed May 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,140 |
Reported balance
After 2023-05-23 transaction · row 1
1 source rowRow 1 · 2023-05-23 · Grant · Acquired 4,190 · Balance 33,140 F1: Restricted stock units granted on May 23, 2023. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on May 23, 2023. Price not applicable.
Coherus Oncology, Inc.
Report date January 11, 2021 · Filed January 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.58 · Expires 2031-01-11 | Direct | 20,000 |
Reported balance
After 2021-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-11 · Grant · Acquired 20,000 · Balance 20,000 F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
GERON CORP
Report date May 21, 2025 · Filed May 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.34 · Expires 2035-05-20 | Direct | 180,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 180,000 · Balance 180,000 F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the Reporting Person's continuous service with the Issuer through such dates.
SUTRO BIOPHARMA, INC.
Report date September 26, 2018 · Filed September 27, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2028-09-25 | Direct | 26,033 |
Reported balance
After 2018-09-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-26 · Grant · Acquired 26,033 · Balance 26,033 F1: The option vests as to 2.778% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 2.778% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.
Spyre Therapeutics, Inc.
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2032-06-06 | Direct | 43,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 43,000 · Balance 43,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2019 Filed Jun 19, 2019 16:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,750 | $21.51 | $80,662.50 |
DisclosureSEC source: 0001567619-19-013660 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 1, 2019. Read SEC document |
| June 07, 2019 Filed Jun 7, 2019 16:52 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 12,400 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001567619-19-013074 · doc1.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 Underlying: Common Stock · 12,400 shares Expires 2029-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2019 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 23:23 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000886744-19-000062 · edgar.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:06 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012972 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,590 F1 · price: Restricted stock units granted on June 4, 2019. Price not applicable. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,150 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-19-007874 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,150 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,150 | $89.76 | $192,984.00 |
DisclosureSEC source: 0001567619-19-007874 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,160 F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. Read SEC document |
| March 27, 2019 Filed Mar 29, 2019 22:30 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,150 | $14.39 | $30,938.50 |
DisclosureSEC source: 0001567619-19-007874 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. Read SEC document |
| January 11, 2019 Filed Jan 30, 2019 16:08 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.37 | $0.00 |
DisclosureSEC source: 0000899243-19-002193 · doc4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 23:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,150 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-18-008811 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,150 Underlying: Common Stock · 2,150 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 23:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,150 | $82.53 | $177,439.50 |
DisclosureSEC source: 0001567619-18-008811 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,160 F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. Read SEC document |
| December 27, 2018 Filed Dec 28, 2018 23:23 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,150 | $14.39 | $30,938.50 |
DisclosureSEC source: 0001567619-18-008811 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 23:02 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,150 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-18-003290 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 Underlying: Common Stock · 2,150 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 23:02 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,150 | $97.93 | $210,549.50 |
DisclosureSEC source: 0001567619-18-003290 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,160 F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. Read SEC document |
| September 27, 2018 Filed Sep 28, 2018 23:02 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,150 | $14.39 | $30,938.50 |
DisclosureSEC source: 0001567619-18-003290 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. Read SEC document |
| September 26, 2018 Filed Sep 27, 2018 18:00 UTC | SUTRO BIOPHARMA, INC. STRO · Entity 5797 | GrantStock Option (right to buy Common Stock) · Derivative | 26,033 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052487 · doc4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,033 Underlying: Common Stock · 26,033 shares Expires 2028-09-25 F1 · derivative.exercise_date: The option vests as to 2.778% of the total shares monthly, beginning on October 26, 2018, with 100% of the total shares vested and exercisable on September 26, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| July 13, 2018 Filed Jul 17, 2018 16:27 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 36,800 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001140361-18-032716 · doc1.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,800 Underlying: Common Stock · 36,800 shares Expires 2028-07-12 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 36 equal monthly installments beginning on August 13, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 21:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,150 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001140361-18-030752 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,450 Underlying: Common Stock · 2,150 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 21:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,150 | $93.52 | $201,068.00 |
DisclosureSEC source: 0001140361-18-030752 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,160 F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. Read SEC document |
| June 27, 2018 Filed Jun 29, 2018 21:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,150 | $14.39 | $30,938.50 |
DisclosureSEC source: 0001140361-18-030752 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on June 12, 2018. Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 00:42 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-027790 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,160 F1 · price: Restricted stock units granted on June 5, 2018. Price not applicable. Read SEC document |
| May 15, 2018 Filed May 17, 2018 20:45 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0000886744-18-000034 · edgar.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2028-05-14 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 23:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 3,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-019095 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F2 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 23:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,750 | $85.00 | $318,750.00 |
DisclosureSEC source: 0001140361-18-019095 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,860 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. Read SEC document |
| April 17, 2018 Filed Apr 19, 2018 23:19 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,750 | $38.59 | $144,712.50 |
DisclosureSEC source: 0001140361-18-019095 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:07 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000899243-18-002888 · doc4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy Common Stock) · Derivative | 3,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-000921 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F4 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,750 | $88.84 | $333,150.00 |
DisclosureSEC source: 0001140361-18-000921 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,860 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F3 · price: All shares sold at the same price. F2 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to exclude 1,050 shares as previously reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,750 | $38.59 | $144,712.50 |
DisclosureSEC source: 0001140361-18-000921 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F2 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to exclude 1,050 shares as previously reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy) Common Stock · Derivative | 3,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-17-035905 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 3,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F3 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,750 | $91.26 | $342,225.00 |
DisclosureSEC source: 0001140361-17-035905 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,910 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. F2 · price: All shares sold at the same price. Read SEC document |
| September 15, 2017 Filed Sep 19, 2017 19:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,750 | $38.59 | $144,712.50 |
DisclosureSEC source: 0001140361-17-035905 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 22:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (right to buy) Common Stock · Derivative | 3,750 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-17-025622 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 3,750 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017 F3 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 22:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,750 | $90.00 | $337,500.00 |
DisclosureSEC source: 0001140361-17-025622 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,910 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017 F2 · price: All shares sold at the same price. Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 22:31 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,750 | $38.59 | $144,712.50 |
DisclosureSEC source: 0001140361-17-025622 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 9, 2017 Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy) Common Stock · Derivative | 4,910 | $0.00 Strike: $89.60 | $0.00 |
DisclosureSEC source: 0001140361-17-024514 · doc1.xml · derivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2027-06-05 F2 · derivative.exercise_date: Option grant vests in full on June 6, 2018. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-024514 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,910 F1 · price: Restricted stock units granted on June 6, 2017. Price not applicable. Read SEC document |
| May 17, 2017 Filed May 19, 2017 16:06 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $23.80 | $0.00 |
DisclosureSEC source: 0000899243-17-013896 · doc4.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 17, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| May 09, 2017 Filed May 11, 2017 00:52 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000886744-17-000029 · edgar.xml · derivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-05-09 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the company through such dates. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy) Common Stock · Derivative | 7,500 | $0.00 Strike: $17.33 | $0.00 |
DisclosureSEC source: 0001140361-17-010367 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2017-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction made pursuant to a 10b5-1 trading plan executed on June 6, 2016. F3 · derivative.exercise_date: Original option grant vests 6/48ths on December 7, 2007, and 1/48th on the 7th day of every month thereafter F4 · balance_after: Reflects the number of stock options that remain outstanding from this specific stock grant following the reported transaction. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 7,500 | $95.00 | $712,500.00 |
DisclosureSEC source: 0001140361-17-010367 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,860 F1 · date: Transaction made pursuant to a 10b5-1 trading plan executed on June 6, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 23:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 7,500 | $17.33 | $129,975.00 |
DisclosureSEC source: 0001140361-17-010367 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: All shares were sold at the same price. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 18:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy) Common Stock · Derivative | 7,500 | $0.00 Strike: $17.33 | $0.00 |
DisclosureSEC source: 0001140361-16-086257 · doc1.xml · derivative · entry 3 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2017-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction made pursuant to a 10b5-1 trading plan executed on June 6, 2016. F3 · derivative.exercise_date: Original option grant vests 6/48ths on December 7, 2007, and 1/48th on the 7th day of every month thereafter F4 · balance_after: Reflects the number of stock options that remain outstanding from this specific stock grant following the reported transaction. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 18:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 7,500 | $95.00 | $712,500.00 |
DisclosureSEC source: 0001140361-16-086257 · doc1.xml · nonDerivative · entry 2 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,860 F1 · date: Transaction made pursuant to a 10b5-1 trading plan executed on June 6, 2016. F2 · price: All shares were sold at the same price. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 18:59 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 7,500 | $17.33 | $129,975.00 |
DisclosureSEC source: 0001140361-16-086257 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Transaction made pursuant to a 10b5-1 trading plan executed on June 6, 2016. Read SEC document |
| June 06, 2016 Filed Oct 13, 2017 23:35 UTC Amendment | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | OtherCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-038676 · doc1.xml · nonDerivative · entry 1 LAWLIS V BRYAN · CIK 0001247681 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,360 F1 · balance_after: On June 8, 2016, the reporting person filed a Form 4 which inadvertently reported an incorrect total amount of securities beneficially owned following the reported transaction. This amendment corrects such total. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.